CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies-Reference-Cited by-同舟云学术

CD7 targeted “off-the-shelf” CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignancies

Published:2023-09-12 Issue:11 Volume:37 Page:2176-2186
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Li Shiqi,Wang Xinxin,Liu Lin,Liu Jia,Rao Jun,Yuan Zhongtao,Gao Li,Li Yu,Luo Le,Li Gui,Li Zhimin,Li Sheng,He Jiaping^ORCID,Zhang Lihua,Chen Lvzhe,Huang Wenhui,Yin Ping,Li Chunmin,Li Xiaoping,Wang Youcheng,Dong Yancheng,Zhang Dingsong,Zang Qingying,Chen Yingnian,Shen Lianjun,Li Wenling,Cao Wei,Zhang Xi^ORCID,Wang Sanbin^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

https://www.nature.com/articles/s41375-023-02018-4.pdf

Reference22 articles.

1. Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia. Blood. 2017;129:1134–42.

2. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, et al. T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood. 2009;114:5136–45.

3. Alcantara M, Tesio M, June CH, Houot R. CAR T-cells for T-cell malignancies: challenges in distinguishing between therapeutic, normal, and neoplastic T-cells. Leukemia. 2018;32:2307–15.

4. Li S, Wang X, Yuan Z, Liu L, Luo L, Li Y, et al. Eradication of T-ALL cells by CD7-targeted universal CAR-T cells and initial test of ruxolitinib-based CRS management. Clin Cancer Res. 2020;27:1242–46.

5. Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol. 1994;152:517–26.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD7 allogeneic WU-CART-007 in patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma: a phase 1/2 trial;2024-08-05

2. Genome editing approaches for universal chimeric antigen receptor T cells;EJC Paediatric Oncology;2024-06

3. Selective targeting of malignant T cells;Nature Cancer;2024-05-30

4. Stable engraftment, as well as graft versus host disease‐free and relapse‐free survival brought by the combination of CD7 targeted universal chimeric antigen receptor‐T, and donor hemopoietic stem cells: Indication of a case report;eJHaem;2024-05-15

5. CAR-T CELL THERAPY FOR T-CELL MALIGNANCIES;Mediterranean Journal of Hematology and Infectious Diseases;2024-02-29